Category: Volcano Corp.
Here's a look at some of the top Wall Street stories for medical device companies this week: Boston Scientific could take CRM lead; Orthofix CFO bails after 6 months amid deepening financial fix; Fourth time's the charm: pSivida, Alimera jump on FDA nod for Iluvien; Echo Therapeutics is on the ropes; Activist investor erupts at Volcano
, Boston Scientific
, Echo Therapeutics Inc.
, Engaged Capital
, Food & Drug Administration (FDA)
, Leerink Swann
, Orthofix International
, pSivida Corp.
, St. Jude Medical
, Alimera Sciences
Activist investor fund Engaged Capital ups the pressure on Volcano Corp., scolding it for its $116 million AtheroMed acquisition and missing chances to sell itself at a premium.
Here's a look at some of the top legal news stories for medical device companies this week: Boston Scientific reveals federal probe of BridgePoint buy, sales; Court defines 'breast implant' in Dow Corning's $2B product liability saga; Apex fights to get respiratory masks back in Germany; St. Jude and Volcano call a cease-fire
St. Jude Medical and Volcano agree to settle all litigation between them, putting to bed years of lawsuits over medical lasers and fractional flow reserve devices.
The Mass. Supreme Judicial Court denies St. Jude Medical's bid to overturn the portions of a lower court's ruling that went against it in its laser technology spat with Volcano Corp.
The highest court in Massachusetts largely denied
Jorge Quinoy, president of Volcano Corp.'s U.S. & APLAC commercial sales, is leaving the company effective today.
Volcano (NSDQ:VOLC) said last week that its president for U.S. & APLAC commercial sales, Jorge (George) Quinoy, is leaving the company effective today.
Here's a look at some of the top regulatory stories for medical device companies this week: Seven questions raised by Medtronic's $43B Covidien acquisition; Medtronic, Covidien merger: Good or bad for medtech innovation?; Medtronic, Covidien merger: Mass. Gov. Deval Patrick says he's had no contact with either company; Volcano closes $117M AtheroMed buy; Incubator group buys prostate treatment tech from Endo Health.